Abstract 5367
Background
Treatment of extremital sarcoma patients may be associated with significant functional disabilities affecting quality of life (QoL) and therefore the return-to-work (RtW) process. Many studies report on RtW and QoL in childhood, adolescents and young adult cancer survivors of different malignancies. In contrast, studies looking at adult sarcoma patients in particular are limited.
Methods
Patients with the diagnosis of an extremital sarcoma of soft tissue and bone, surgically treated between 2000 and 2015, age at diagnosis of ≥ 18 or < 65 (age of retirement in Switzerland), alive and without evidence of sarcoma disease were invited for an interview. The primary objective was to investigate the employment rate. Secondary aims were to assess biomedical predictors of RtW and investigate the present QoL of adult sarcoma survivors. Health-related QoL measurements including physical, mental, and social domains were investigated with the following questionnaires: TESS (The Toronto Extremity Salvage Score), SF-36 (short-form health survey), CES-D (Center for Epidemiologic Studies-Depression Scale) and FoP-Q-SF (fear of progression).
Results
5 out of 45 (11.1%) interviewed patients did not return to work. In the univariate analysis no statistically significant parameter predicting RtW could be detected. High educational level and full-time employment before sarcoma diagnosis showed a non-significant tendency towards predicting increased RtW probability. In the multivariate analysis full-time employment before sarcoma diagnosis is a significant predictor of RtW (OR 9.828 (1.318 – 73.303)) whereas high educational level does not show a significant influence. Neither the SF-36 physical and mental summary score nor the scores of the other interviews significantly correlated with RtW outcome. However, the mean difference in the FoP-Q-SF- score between the two groups (no RtW and RtW) was -10.981 (-18.242 to -3.720) in the multivariate model. Age at diagnosis, gender, type of sarcoma, tumor site/grade, amputation rate, Whoops procedure did not correlate with rate of RtW.
Conclusions
Our study reveals a high employment rate and good QoL of adult sarcoma survivors. Part-time employment and fear of progression might hamper the RtW process.
Clinical trial identification
Legal entity responsible for the study
Kollar Attila.
Funding
Swiss Cancer League/Swiss Cancer Research.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract